Physician profile
Meg A Lemon
NPI 1902845985
$6,317.18
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $766 · 2020: $390 · 2021: $1,103 · 2022: $1,881 · 2023: $1,996 · 2024: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,077 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,077.19 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,527.74 | 2019-2024 | |
| Janssen Biotech, INC. | $636.91 | 2019-2023 | Tremfya |
| Sun Pharmaceutical Industries INC. | $528.88 | 2019-2024 | Ilumya, Winlevi, Absorica Ld |
| Leo Pharma INC. | $496.51 | 2021-2023 | Adbry |
| Novartis Pharmaceuticals Corporation | $406.46 | 2019-2023 | |
| Lilly USA, LLC | $347.76 | 2019-2023 | Olumiant, Taltz |
| E.R. Squibb & Sons, L.L.C. | $337.67 | 2022-2023 | Sotyktu |
| Genzyme Corporation | $318.22 | 2019-2023 | |
| Ucb, INC. | $246.81 | 2021-2024 | Cimzia, Bimzelx |
| Pfizer INC. | $220.09 | 2019-2023 | |
| Amgen INC. | $192.88 | 2019-2024 | Otezla |
| Regeneron Healthcare Solutions, INC. | $131.81 | 2019-2023 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.30 | 2022-2023 | Cyltezo |
| Helsinn Therapeutics (U.S.), INC. | $114.49 | 2021-2023 | Valchlor |
| Galderma Laboratories, L.P. | $114.21 | 2019-2023 | Epsolay |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $101.69 | 2021-2023 | Opzelura |
| Dermavant Sciences, INC. | $64.79 | 2023 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $63.77 | 2022-2023 | Targretin |
| Merz North America, INC. | $62.65 | 2019-2022 | |
| Celgene Corporation | $60.54 | 2019 | |
| Allergan, INC. | $44.95 | 2022 | |
| Prugen, INC. Pharmaceuticals | $34.76 | 2019-2020 | |
| Biofrontera INC. | $31.25 | 2019 | |
| Organogenesis INC. | $23.64 | 2023 | Puraply |
| Journey Medical Corporation | $21.18 | 2023 | |
| Ani Pharmaceuticals, INC. | $20.60 | 2022 | |
| Organon LLC | $17.76 | 2023 | Hadlima |
| Kyowa Kirin, INC. | $15.23 | 2022 | |
| Dermira, INC. | $14.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meg Lemon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.